Taurian & Contreras (2000). Interactions that define the alkylamine side-chain conformation in phenylalkylamine hallucinogens: an ab initio study. Journal of Molecular Structure.
West et al. (2000). Antagonism of a PCP drug discrimination by hallucinogens and related drugs. Neuropsychopharmacology.
Abraham (2001). New hope for Hallucinogen-Induced Persistent Perceptual Disorder? Journal of Clinical Psychopharmacology.
Aldurra & Crayton (2001). Improvement of hallucinogen persisting perception disorder by treatment with a combination of fluoxetine and olanzapine: case report. Journal of Clinical Psychopharmacology.
And & Horton (2001). Demographic effects on the trail making test in hallucinogen abusers. International Journal of Neuroscience.
De Rios (2001). In memory of Oscar Janiger, pioneer in psychedelic research. Journal of Psychoactive Drugs.
Grinspoon & Doblin (2001). Psychedelics as catalysts of insight-oriented psychotherapy. Social Research.
Halpern & Pope (2001). Hallucinogens on the Internet: a vast new source of underground drug information. The American Journal of Psychiatry.
Heilig (2001). Tripping: An anthology of true-life psychedelic adventures. Journal of Psychoactive Drugs.
Hurtley (2001). Psychedelic Trafficking. Science.
Golub et al. (2001). Is the U.S. experiencing an incipient epidemic of hallucinogen use? Substance Use & Misuse.
Klotter (2001). Psychedelic plants (for psychotherapeutics). Townsend Letter for Doctors and Patients.
Klotter (2001). The brain's endogenous psychedelic. Townsend Letter for Doctors and Patients.
Lerner et al. (2001). LSD-induced Hallucinogen Persisting Perception Disorder treated with clonazepam: two case reports. The Israel Journal of Psychiatry and Related Sciences.
Marek et al. (2001). A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex. Neuroscience.
Riba et al. (2001). Psychometric assessment of the Hallucinogen Rating Scale. Drug and Alcohol Dependence.
Winkelman (2001). Psychointegrators: multidisciplinary perspectives on the therapeutic effects of hallucinogens. Complementary Health Practice Review.
Clare (2002). QSAR of benzene derivatives: comparison of classical descriptors, quantum theoretic parameters and flip regression, exemplified by phenylalkylamine hallucinogens. Journal of Computer-Aided Molecular Design.
De Rios, Grob & Baker (2002). Hallucinogens and redemption. Journal of Psychoactive Drugs.
Frankel & Cunningham (2002). The hallucinogen d-lysergic acid diethylamide (d-LSD) induces the immediate-early gene c-Fos in rat forebrain. Brain Research.
Horton & Roberts (2002). Derived trail making test indices in a sample of hallucinogen abusers: demographic effects. International Journal of Neuroscience.
Lerner et al. (2002). Flashback and Hallucinogen Persisting Perception Disorder: clinical aspects and pharmacological treatment approach. The Israel Journal of Psychiatry and Related Sciences.
Nichols, Ronesi & Sanders-Bush (2002). Hallucinogens and Drosophila: linking serotonin receptor activation to behavior. Neuroscience.
Rabin et al. (2002). 5-HT 2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens. Pharmacology, Biochemistry and Behavior.
Wilcox, Wagner & Anthony (2002). Exposure opportunity as a mechanism linking youth marijuana use to hallucinogen use. Drug and Alcohol Dependence.
Eckler et al. (2003). Behavioral characterization of 2- O-desmethyl and 5- O-desmethyl metabolites of the phenylethylamine hallucinogen DOM. Pharmacology, Biochemistry and Behavior.
Fadiman et al. (2003). Psychedelic research revisited. Journal of Transpersonal Psychology.
Fantegrossi, Woods & Winger (2004). Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behavioural Pharmacology.
Halpern (2003). Hallucinogens: An update. Current Psychiatry Reports.
Halpern (2003). Hallucinogen persisting perception disorder: what do we know after 50 years? Drug and Alcohol Dependence.
Hubbard & Ramachandran (2003). Refining the experimental lever: A reply to Shanon and Pribram. Journal of Consciousness Studies.
Kendler et al. (2003). Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. The American Journal of Psychiatry.
Lerner et al. (2003). Clonazepam treatment of lysergic acid diethylamide-induced hallucinogen persisting perception disorder with anxiety features. International Clinical Psychopharmacology.
Scruggs, Schmidt & Deutch (2003). The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats. Neuroscience Letters.
Sprinkle (2003). How psychedelics informed my sex life and sex work. Sexuality & Culture.
Tolbert (2003). Gender and psychedelic medicine: Rebirthing the archetypes. ReVision.
Vogel (2003). Female shamanism, goddess cultures, and psychedelics. ReVision.
Check (2004). Psychedelic drugs: the ups and downs of ecstasy. Nature.
Halpern (2004). Hallucinogens and dissociative agents naturally growing in the United States. Pharmacology and Therapeutics.
King & Molnar (2004). A study of ring‐substituent influence on pharmacological activity in a series of phenethylamine‐type psychedelics. International Journal of Quantum Chemistry.
Nichols (2004). Hallucinogens. Pharmacology and Therapeutics.
Smith et al. (2004). Do drugs have religious import? A 40-year retrospective. Journal of Humanistic Psychology.
Tanne (2004). Humphry Osmond. British Medical Journal.
Baker (2005). Psychedelic sacraments. Journal of Psychoactive Drugs.
Chung & Martin (2005). Classification and short-term course of DSM-IV cannabis, hallucinogen, cocaine, and opioid disorders in treated adolescents. Journal of Consulting and Clinical Psychology.
Crowley et al. (2005). A role for psychedelics in psychiatry? The British Journal of Psychiatry.
Dobkin de Rios (2005). Eminence Grise: Psychedelic researchers tell it all. PsycCRITIQUES.
Espiard et al. (2005). Hallucinogen persisting perception disorder after psilocybin consumption: a case study. European Psychiatry.
Fantegrossi et al. (2005). Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology.
Klotter (2005). End-of-life & psychedelic research. Townsend Letter for Doctors and Patients.
Ott et al. (2005). Evidence for a common biological basis of the Absorption trait, hallucinogen effects, and positive symptoms: epistasis between 5-HT2a and COMT polymorphisms. American Journal of Medical Genetics.
Sandison (2005). A role for psychedelics in psychiatry? The British Journal of Psychiatry.
Sessa (2005). Can psychedelics have a role in psychiatry once again? The British Journal of Psychiatry.
Sessa (2005). "A role for psychedelics in psychiatry?": Author's reply. The British Journal of Psychiatry.
Weinstein (2005). Hallucinogen actions on 5-HT receptors reveal distinct mechanisms of activation and signaling by G protein-coupled receptors. The AAPS Journal.
Arnone & Schifano (2006). Psychedelics in psychiatry. The British Journal of Psychiatry.
Corbin (2006). Facing our dragons: Spiritual activism, psychedelic mysticism and the pursuit of opposition. Human Architecture.
Eldridge & Hillenbrand (2006). Hallucinogens. Pediatrics in Review.
Friedman (2006). The renewal of psychedelic research: implications for humanistic and transpersonal psychology. The Humanistic Psychologist.
Neidpath (2006). Reviving research into psychedelic drugs. The Lancet.
Lambe & Aghajanian (2006). Hallucinogen-induced UP states in the brain slice of rat prefrontal cortex: role of glutamate spillover and NR2B-NMDA receptors. Neuropsychopharmacology.
Leitner (2006). Psychedelic psychology. PsycCRITIQUES.
Lerner & Lyvers (2006). Values and beliefs of psychedelic drug users: a cross-cultural study. Journal of Psychoactive Drugs.
Marek et al. (2006). 5-Hydroxytryptamine 2A (5-HT 2A) receptor regulation in rat prefrontal cortex: Interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740. Neuroscience Letters.
Morris (2006). Hallucinogen research inspires "neurotheology". Lancet Neurology.
Sessa (2006). "Psychedelics in psychiatry": Reply. The British Journal of Psychiatry.
Stone, Storr & Anthony (2006). Evidence for a hallucinogen dependence syndrome developing soon after onset of hallucinogen use during adolescence. International Journal of Methods in Psychiatric Research.
Walsh & Grob (2006). Early psychedelic investigators reflect on the psychological and social implications of their research. Journal of Humanistic Psychology.
Benneyworth, Smith & Sanders-Bush (2007). Chronic phenethylamine hallucinogen treatment alters behavioral sensitivity to a metabotropic glutamate 2/3 receptor agonist. Neuropsychopharmacology.
Bonn-Miller et al. (2007). Associations between psychedelic use, abuse, and dependence and lifetime panic attack history in a representative sample. Journal of Anxiety Disorders.
Gillespie et al. (2007). Factor and item‐response analysis DSM‐IV criteria for abuse of and dependence on cannabis, cocaine, hallucinogens, sedatives, stimulants and opioids. Addiction.
González-Maeso et al. (2007). Hallucinogens recruit specific cortical 5-HT 2A receptor-mediated signaling pathways to affect behavior. Neuron.
Jones (2007). The creativity of Crumb: research on the effects of psychedelic drugs on the comic art of Robert Crumb. Journal of Psychoactive Drugs.
Lambe & Aghajanian (2007). Prefrontal cortical network activity: Opposite effects of psychedelic hallucinogens and D1/D5 dopamine receptor activation. Neuroscience.
Letcher (2007). Mad thoughts on mushrooms: Discourse and power in the study of psychedelic consciousness. Anthropology of Consciousness.
Mashour (2007). From LSD to the IRB: Henry Beecher's psychedelic research and the foundation of clinical ethics. International Anesthesiology Clinics.
Stone et al. (2007). Who is becoming hallucinogen dependent soon after hallucinogen use starts? Drug and Alcohol Dependence.
Celada et al. (2008). The hallucinogen DOI reduces low-frequency oscillations in rat prefrontal cortex: reversal by antipsychotic drugs. Biological Psychiatry.
Erritzoe et al. (2008). Decreased serotonin-2A binding in MDMA and hallucinogen users: An [18F]altanserin PET study. NeuroImage.
Fadiman (2008). Psychedelic medicine: New evidence for hallucinogenic substances as treatment. Journal of Transpersonal Psychology.
Fantegrossi et al. (2008). Hallucinogen-like effects of N, N-dipropyltryptamine (DPT): Possible mediation by serotonin 5-HT 1A and 5-HT 2A receptors in rodents. Pharmacology, Biochemistry and Behavior.
Fantegrossi et al. (2008). The behavioral pharmacology of hallucinogens. Biochemical Pharmacology.
Frood (2008). Healing hallucinogens: psychoactive drugs are undergoing a renaissance as researchers turn to them to bring relief to patients with difficult-to-treat conditions. Chemistry and Industry.
Johnson, Richards & Griffiths (2008). Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology.
Luke (2008). Psychedelic substances and paranormal phenomena: A review of the research. Journal of Parapsychology.
Luke (2008). Psychedelic Medicine: New evidence for hallucinogenic substances as treatments. Drugs and Alcohol Today.